International: +1-347-960-6455

Research Reports

Filter By Therapeutic Area

Filtered by Therapeutic Areas (Oncology)

Oncology
Cyclin-Dependent Kinase (CDK) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cyclin-dependent kinases (CDKs) can be identified as protein kinases that require a separate cyclin subunit, which provides domains for enzymatic activity. CDKs play a major role in modulating transcription and controlling cell division.

Oncology
Bromodomain and Extraterminal Domain (BET) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Bromodomain and extraterminal domain (BET) proteins are identified as epigenetic readers and can be characterized by the presence of two tandem bromodomains (BD1 and BD2), extraterminal domain (ET), and a C-terminal domain (CTD).

Oncology
Rectal Cancer Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Rectal cancer refers to formation of malignant cells inside the rectum. This type of cancer develops over several years, first growing as a polyp, which is precancerous growth. Whereas, some polyps can turn into cancer.

Oncology
Mechanistic Target of Rapamycin (mTOR) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Mechanistic target of rapamycin (mTOR) is a threonine and serine protein kinase that is a great target for immunosuppressive drug rapamycin. There are two distinct complexes of mTOR: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).

Oncology
Pancreatic Cancer Therapeutics - Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019
Report Category Competitive Landscape Reports

Pancreatic cancer results in the development of malignant cells in the pancreas, which leads to the formation of tumor. The tumor can be further categorized into exocrine tumor and endocrine tumor.

Oncology
Pancreatic Cancer Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Pancreatic cancer is marked by development of malignant cells in the pancreas, resulting in the formation of tumor. The disease is further classified into two main groups: endocrine and exocrine tumors. Endocrine tumors, also known as islet cell tumors or neuroendocrine tumors, are less common and most often benign. On the other hand, exocrine tumors or adenocarcinomas forms in the pancreas ducts.

Oncology
OX40 Receptor Agonists – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

OX40 receptor belongs to tumor necrosis factor (TNF) superfamily, whose interactions play an important role in the development of various autoimmune diseases.

Oncology
Oral Mucositis (OM) Therapeutics – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Oral mucositis (OM) is the most common side-effects of cancer treatment (chemotherapy and/or radiotherapy), and occurs usually in the people suffering from head and neck cancer.

Oncology
Proteasome Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Proteasomes are minute, tub-shaped structures found in cells and are responsible for the breakdown of misfolded and non-functional proteins inside the cells. It is a multi-subunit enzyme complex that plays a central role in the regulation of proteins responsible for controlling cell-cycle progression and apoptosis, and has therefore, become an important target for anti-cancer therapy.

Oncology
Pancreatic Cancer Therapeutics – Market Analysis, Patents, Designations, Collaborations, and Other Developments
Report Category Marketed Drug Insights and Forecast Reports

Pancreatic cancer instigates in the tissues of pancreas — an organ in the abdomen that lies horizontally behind the lower part of the stomach. Pancreas releases enzymes and hormones, which help in digestion and maintaining blood sugar level in the body.

Oncology
Pancreatic Cancer – Epidemiology Insights (2016-2028)
Report Category Epidemiology Insights and Forecast Reports

Pancreatic cancer involves the development of malignant cells in the pancreas, resulting in the formation of tumor. The disease is further classified into two main groups: endocrine and exocrine tumors.

Oncology
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

NF-κB is identified as a family of highly conserved transcription factors, which are responsible for many cellular functions such as regulation of inflammatory responses, apoptosis, cellular growth, and others.

Oncology
Myelofibrosis (MF) Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

MF is a rare disease identified by the presence of excessive scar tissues in bone marrow that decreases the hematopoietic capacity of the bone marrow. The genetic mutation in the blood stem cells causes MF.

Oncology
Interleukin-6 (IL-6) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

IL-6 is transcribed by IL-6 gene that encodes a cytokine, which functions in inflammation and maturation of B cells. The IL-6 protein can induce fever in patients suffering from autoimmune diseases, thereby acting as endogenous pyrogens.

Oncology
Janus Kinase (JAK) Inhibitors - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

JAK consists of four intracellular non-receptor tyrosine kinases that help in cytokine mediated signaling through the JAK-STAT pathway. It contains two almost identical phosphate transferring domains in which one domain shows kinase activity and the other regulates the activity of the first via negative inhibition.

Oncology
Mitochondrial-Based Therapeutics Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Mitochondria (singular: mitochondrion) are cytoplasmic organelles found in eukaryotic cells, such as plants, animals, fungi, and protists. The number of mitochondria present in a eukaryotic cell depend on the metabolic requirements of that cell; and ranges from a single large mitochondrion to thousands of the organelles.

Oncology
Wnt Signaling Pathway Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Wnt or β-Catenin signaling pathway plays a key role in the development of pluripotent cells and embryonic development. The pathway regulates cell-to-cell interaction, activates blastocyst, accelerates trophoblast development, accelerate chorion-allantois fusion and implantation.

Oncology
Galectin Inhibitor Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways.

Oncology
Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Epidermal growth factor receptors (EGFR) are a group of receptor tyrosine kinase (RTK) that plays a major role in cell proliferation, survival and differentiation. In most of the cancer, EGFR are amplified and overexpressed, due to dysregulation, resulting in cancer development.

Oncology
Endothelin Antagonists Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Endothelin antagonists are drug candidates that acts against endothelin receptors and generate pharmacological actions such as blocking the vasoconstriction and mediate vasodilatation. Endothelin-1 is a peptide which is comprised of 21 amino acids and formed by vascular endothelium.

Oncology
Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation.

Oncology
MDM2 Protein Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers.

Oncology
Interleukin Receptor Modulators Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Interleukin receptors are a group of cytokine receptors that are expressed by leukocytes. Interleukin receptors play an important role in the functioning of the immune system.

Oncology
Interleukin 8 Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Interleukin 8 is a chemokine produced by various immune cells. They promote angiogenesis, proliferation and development of cancerous cells. The other diseases which are associated with interleukin 8 are depression, schizophrenia, bipolar disorder, migraine, Alzheimer’s disease, colitis, rheumatoid arthritis, multiple sclerosis, asthma, allergic rhinitis, psoriasis, eczema and others.

Oncology
Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth.

Oncology
Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Glycogen synthase kinase 3 beta (GSK-3β) is an attractive target for the treatment of psychiatric disorders and neurodegenerative diseases. Many GSK-3β inhibitors have been developed for the treatment of different central nervous system disorders.

Oncology
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways.

Oncology
RNA Interference (RNAi) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

RNA interference (RNAi) is a molecule type that silences the gene and limits the transcription of the mutated gene. Gene silencing is a novel mechanism that inactivates the transcripts of mutated gene, by activating sequence specific RNA degradation process.

Oncology
Rho Kinase Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Rho kinase inhibitor, also known as ROCK inhibitor, inhibits the rho kinases, a family of small GTP-binding protein. Rho kinases are found to regulate cell motility, proliferation, shape, gene expression, apoptosis, and are also involved in the signalling pathway.

Oncology
p53 Antigen Modulators Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

p53 is the tumor suppressor transcription factor that activates to various stimulus, including uncontrolled cell proliferation, oncogene over-expression, and DNA damage. p53 antigen modulators helps in preventing cancer development through regulation of cell cycle and apoptosis.

Oncology
Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) plays important role in the T-cell regulation at an early stage of naive T-cell activation, primarily in the lymph nodes. CTLA-4 has emerged as an attractive cancer immunotherapy as a part of “immune checkpoint blockade”.

Oncology
Cyclophilin Inhibitors Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cyclophilin befits in the group of protein that shows peptidyl-prolyl cis-trans isomerase activity, found in all types of cells. In humans, 16 cyclophilins have been identified till date. Cyclophilin A, a member of cyclophilin group, mediate the action of immunosuppressive drugs.

Oncology
Cell Cycle Inhibitors Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cell cycle inhibitors include cyclin inhibitors and cyclin-dependent kinases (CDKs), which plays major role in developing new class of anti-cancer therapies. Also, cell cycle inhibitors in combination with chemotherapy, overcome drug resistance and improve cytotoxic efficacy. CDKs are rational targets for cancer treatment, that could restore cell-cycle checkpoints and may induce apoptosis.

Oncology
Cathepsin K Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Cathepsin K is a protease enzyme which is coded by CTSK gene. The function associated with the gene involves bone remodelling and resorption. Cathepsin K is a member of peptidase C1 protein family and expressed mainly in osteoclasts.

Oncology
Aurora Kinase Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.

Oncology
Angiopoietin (ANG) Inhibitors Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Angiopoietin (ANG) receptor plays a crucial role in regulation of vascular permeability and pathological vascular remodelling during tumour angiogenesis, metastasis and inflammation. Thus, it has emerged as a new clinical approach for the development of therapeutics which treat cancer and ophthalmological diseases.

Oncology
Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.

Oncology
Androgen Receptor Antagonist Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Androgens are responsible for the development of male characteristics by binding to androgen receptors. Androgen receptor plays an important role in the development and progression of prostate cancer. Thus, it has been an attractive target for the clinical interventions and treatment of prostate cancer.

Oncology
Alpha-Synuclein Inhibitor Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Alpha-synuclein is a protein that is abundantly found in the brain. The minimal amount of alpha-synuclein is also found in the heart and other tissues. The protein is prominently found at the tips of the nerve cells. It helps in the maintaining supply of the synaptic vesicle in presynaptic terminals. In addition, the alpha-synuclein protein also helps in release of dopamine.

Oncology
Tagraxofusp - API Insight, 2018
Report Category Marketed API Reports

Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3.

Oncology
Dasatinib - Drug Insight and Forecast, 2018
Report Category Marketed Drug Insights and Forecast Reports

Dasatinib (Sprycel) medicines are generally used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who have been tested positive for the Philadelphia chromosome (Ph+).

Oncology
Cabozantinib- API Insight, 2018
Report Category Marketed API Reports

Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.

Oncology
Myelodysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Report Category Epidemiology Insights and Forecast Reports

Myelodysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity.

Oncology
Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Mechanism of Action Reports

Akt, also known as PKB, is generally activated in several types of cancers such as breast, gastric, lung, ovary, and pancreatic cancer. Akt inhibitor prevent the functioning of activated form of Akt kinases. Akt kinases are also involved in promoting growth factor-mediated cells that mediates cell proliferation and inhibition of apoptosis through the inactivation of pro-apoptotic proteins, such as mouse double minute 2 homolog (MDM2) and Bcl-2 antagonist of cell death.

Oncology
Uveal Melanoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body. The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia.

Oncology
Tuberous Sclerosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Tuberous sclerosis, also known as tuberous sclerosis complex, is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. It can occur in the brain, skin, kidneys, and other organs, in some cases leading to significant health problems.

Oncology
Thymic Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Thymic carcinoma, also known as thymomas, is a rare type of cancer that forms in the cells present in the outside surface of the thymus. Thymus is a small organ that lies in the upper chest under the breastbone.

Oncology
Sezary Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Sézary syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells present in the skin, lymph nodes and blood. It accounts approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma. Sézary syndrome is more prevalent in males compared to females.

Oncology
Pontine Glioma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Pontine glioma is more prevalent in children than adults.

Oncology
Juvenile Myelomonocytic Leukemia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow.

Oncology
Hypopharyngeal Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Hypopharyngeal cancer, a type of head and neck cancer, develops in hypopharynx. Pharynx is a hollow tube about five inches long, and the bottom part of the pharynx called hypopharynx. Most of the hypopharyngeal malignancy occurs in squamous cells.

Oncology
Hormone Sensitive Breast Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Breast cancer generally occurs when breast cells grow uncontrollably. Mostly, breast cancer development starts in the duct that carries milk to the nipples. Some breast cancer cells develop in milk producing glands. As per the National Institutes of Health (NIH), in the U.S., 14.6% of all new cancer cases diagnosed every year are of breast cancer.

Oncology
Gorlin Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Gorlin syndrome, also known as basal cell nevus syndrome, is an inherited genetic disorder characterized by multiple basal cell skin cancer. The common symptoms observed during Gorlin syndrome are calcium deposition in brain, jaw cysts, skeletal changes and developmental disability.

Oncology
Bone Metastases Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Bone metastases is a common form of cancer of the skeleton that inhabits in bone marrow and stimulates the local bone activity. In this condition, the normal bone homeostasis disrupts which leads to the development of the tumour. Some of the major symptoms observed in patients with bone metastases are bone pain, spinal cord compression, and high blood calcium levels.

Oncology
Angioimmunoblastic T-Cell Lymphoma (AITL) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Angioimmunoblastic T-cell lymphoma is a rare type of peripheral T-cell lymphoma which is characterized by lymphadenopathy, fever, and arthritis. The signs and symptoms associated with the disease include pleural effusion, arthritis, edema, ascites and pruritic skin rash.

Oncology
Acquired Immunodeficiency Syndrome (AIDS) Related Cancer Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Acquired immunodeficiency syndrome (AIDS) related cancer include those types of cancer which occurs in patients suffering from AIDS. People with AIDS are reported to be highly suspected to the occurrence of lymphomas.

Oncology
Adrenocortical Carcinoma Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
Report Category Indication Pipeline Reports

Adrenocortical carcinoma, also known as adrenal cortex carcinoma, is a rare form of cancer that occurs at the cortex layer of the adrenal gland. There are two adrenal glands present in the human body: one at the top of each kidney.